Lyophilized tesamorelin is a synthetic 44-amino acid growth-hormone-releasing hormone (GHRH) analog stabilized via freeze-drying for laboratory research. Evaluated in preclinical models for its high selectivity toward the GHRH receptor, this research compound provides an essential tool for investigating endogenous GH pulsatility, metabolic regulation, and downstream IGF-1 signal transduction.
Lyophilized tesamorelin is a synthetic 44-amino acid growth-hormone-releasing hormone (GHRH) analog stabilized via freeze-drying for laboratory research. Evaluated in preclinical models for its high selectivity toward the GHRH receptor, this research compound provides an essential tool for investigating endogenous GH pulsatility, metabolic regulation, and downstream IGF-1 signal transduction.
Lyophilized tesamorelin is a synthetic peptide analog of naturally occurring growth-hormone-releasing hormone (GHRH), comprised of the 44-amino acid chain of human GHRH modified at the N-terminus with a trans-3-hexenoic acid group. This N-terminal modification enhances enzymatic stability against dipeptidyl peptidase-4 (DPP-IV) degradation, extending its active half-life in experimental setups compared to native GHRH(1-44) amide.
The term "lyophilized" refers to the vacuum freeze-drying process applied during manufacture. By sublimating moisture from the purified peptide solution, lyophilization yields a stable, solid cake or powder. This physical state preserves structural integrity, prevents premature peptide hydrolytic cleavage, and ensures long-term stability during shipping and laboratory storage prior to reconstitution.
Structurally, tesamorelin retains the complete bioactive peptide sequence required to bind and activate the growth-hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor primarily localized on somatotroph cells in the anterior pituitary gland. The addition of the hexenoyl lipophilic moiety at the N-terminal tyrosine residue significantly alters its pharmacokinetic profile without compromising its high receptor selectivity.
In cell culture and membrane-binding assays, tesamorelin exhibits nanomolar affinity for the GHRH receptor. Upon binding, it stimulates adenylate cyclase activity, triggering cyclic adenosine monophosphate (cAMP) accumulation and activating protein kinase A (PKA). This intracellular cascade promotes both the synthesis and pulsatile release of endogenous growth hormone (GH). Investigators utilizing research peptides leverage these specific binding dynamics to isolate pituitary signaling pathways from non-specific secretagogue responses.
The primary mechanism of action for tesamorelin involves selective stimulation of pituitary somatotrophs, prompting the regulated release of somatotropin. Unlike direct growth hormone administration, GHRH analogs preserve the endogenous feedback loops governed by somatostatin (somatotropin release-inhibiting factor) and systemic insulin-like growth factor 1 (IGF-1) levels.
Preclinical studies indicate that tesamorelin-induced GH release stimulates hepatic synthesis of IGF-1. This downstream mediator circulates systemically to engage IGF-1 receptors (IGF-1R) across target tissues, initiating downstream Akt/mTOR signaling pathways involved in cell growth, metabolic regulation, and tissue repair. Detailed evaluations of this cascade can be explored in our growth hormone secretagogues guide.
A major area of preclinical investigation surrounding lyophilized tesamorelin involves its impact on lipid metabolism, adipocyte gene expression, and visceral fat accumulation. Animal models of metabolic dysfunction indicate that GHRH receptor stimulation enhances lipolysis via beta-adrenergic signaling pathways and upregulates key lipolytic enzymes such as hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL).
In rodent models evaluating hepatic steatosis and visceral adiposity, administration of tesamorelin has been associated with reduced intrahepatic triglyceride accumulation and altered lipid flux. In vitro hepatocytes subjected to high-fat culturing conditions demonstrate altered gene expression patterns, specifically the downregulation of lipogenic transcription factors like SREBP-1c. Researchers frequently examine these mechanisms to better understand the intersection between neuroendocrine signaling and metabolic disease models.
Beyond lipid regulation, preclinical models frequently employ tesamorelin to examine tissue preservation, collagen synthesis, and skeletal muscle dynamics. Elevated local and systemic IGF-1 signaling downstream of GHRH activation accelerates protein synthesis pathways while suppressing proteolytic ubiquitin-proteasome pathways in myocytes.
In vitro cellular assays using musculoskeletal cell lines demonstrate increased collagen type I and type III expression following treatment with GHRH receptor agonists. Furthermore, rodent models of tissue injury demonstrate enhanced fibroblast migration and accelerated extracellular matrix re-organization when evaluating the systemic impacts of GHRH analog signaling. Researchers can contextualize these findings within broader ghrh analogs overview documentation.
When designing comparative in vitro or preclinical protocols, researchers often contrast tesamorelin with alternative GHRH receptor agonists and secretagogues. While all native GHRH derivatives act on the same pituitary receptor target, structural alterations impart distinct physical, metabolic, and kinetic profiles.
For example, cjc-1295 no dac represents a truncated 29-amino acid GHRH fragment (Mod GRF 1-29) designed for rapid clearance, whereas sermorelin consists of the unmodified GHRH(1-29) chain. In contrast, tesamorelin maintains the full 44-amino acid sequence with an N-terminal fatty acid addition, providing superior stability against DPP-IV enzymatic cleavage. When comparing GHRH analogs with ghrelin receptor agonists like ipamorelin, researchers note that tesamorelin exclusively targets the pituitary GHRH receptor without directly engaging the growth hormone secretagogue receptor (GHS-R1a).
Proper reconstitution technique is essential to maintain the structural integrity of lyophilized tesamorelin and prevent aggregation or mechanical shearing of the peptide chain. Standard laboratory protocols require strict aseptic technique inside a laminar flow hood using sterile diluents such as bacteriostatic water for injection (0.9% benzyl alcohol) or sterile physiological saline.
To reconstitute, slowly introduce the chosen diluent along the inner glass wall of the vial to minimize direct impact on the lyophilized cake. Allow the solvent to gently saturate the powder without vigorous shaking or vortexing, which can induce protein denaturation and bubble formation. Gentle swirling or slow rotation of the vial ensures complete dissolution into a clear, colorless solution prior to experimental sampling.
In its lyophilized state, high-purity tesamorelin demonstrates excellent shelf stability when stored under controlled environment conditions. Sealed vials should be stored at -20°C or -80°C for long-term preservation, protected from direct light exposure and atmospheric moisture. Standard desiccation preserves the lyophilized matrix against ambient humidity during storage.
Once reconstituted into aqueous solution, the chemical stability of tesamorelin decreases over time due to potential hydrolytic and oxidative degradation pathways. Reconstituted aliquots must be maintained under refrigeration at 2°C to 8°C and evaluated within a defined experimental timeframe. Repeated freeze-thaw cycles of reconstituted liquid must be avoided, as phase changes induce physical stresses that compromise secondary protein structures.
Assuring analytical purity and batch consistency is vital for reproducible experimental outcomes in preclinical research. PX1 Research subjects every lot of lyophilized tesamorelin to rigorous quality control protocols executed by independent ISO 17025 accredited laboratories.
Analytical verification includes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity (consistently exceeding 98.0%), Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight, and Limulus Amebocyte Lysate (LAL) testing to confirm low endotoxin levels (< 0.01 EU/μg). Detailed, lot-traceable Certificates of Analysis (COAs) are made available for every shipment. Academic and enterprise facilities looking to establish supply agreements can consult our wholesale lab account services or access our complete research hub.
What is the certified purity level of PX1 lyophilized tesamorelin?
Every lot of lyophilized tesamorelin provided by PX1 Research is verified via RP-HPLC to meet or exceed a chemical purity threshold of 98.0%.
How should unopened vials of lyophilized tesamorelin be stored?
Unopened, lyophilized vials should be stored at -20°C to -80°C in a dry, dark environment to maintain maximum chemical stability until reconstitution.
What diluent should be used for reconstituting tesamorelin for laboratory assays?
Laboratory protocols typically utilize sterile bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution, depending on the requirements of the specific cell culture or analytical assay.
How does tesamorelin differ structurally from native GHRH?
Tesamorelin contains the full 44-amino acid sequence of human GHRH with the addition of a trans-3-hexenoic acid moiety attached to the N-terminus, which protects the peptide from enzymatic degradation by DPP-IV.
What analytical tests are included on the Certificate of Analysis (COA)?
PX1 Certificates of Analysis include RP-HPLC chromatograms for purity assessment, ESI-MS mass spectrometry spectra for identity verification, micro-analytical water content tests, and LAL assays for endotoxin quantification.
What is the maximum endotoxin threshold for PX1 research peptides?
PX1 Research enforces strict endotoxin controls, ensuring all lot batches pass LAL testing with endotoxin levels strictly below 0.01 EU/μg.
Are bulk purchasing options available for institutional research projects?
Yes, PX1 Research offers institutional supply agreements, bulk quantity pricing, and custom lot reservation through our dedicated wholesale portal.
Is tesamorelin approved for human administration or clinical use?
No. Lyophilized tesamorelin supplied by PX1 Research is strictly designated for laboratory research use only by qualified researchers in preclinical and in vitro experimental settings.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.